Last week, readers were most interested in a story about FDA approving Cleveland Diagnostics' prostate cancer test.
The test, which will use Iso-PAS technology, will be developed by Nipro of Japan in collaboration with other companies, institutes, and nonprofit organizations.
The medical center will use PathAI's AISight Dx image management system to evaluate algorithms for a variety of applications.
The company is developing a noninvasive urine-based test for sexually transmitted infections including chlamydia and gonorrhea.
Hims & Hers obtains YourBio's microsampling tech, which the firm said will speed its efforts to improve blood collection, including outside traditional clinical settings.
NEW YORK – After rising 9 percent in October, the 360Dx Top 30 continued its upward momentum last month, rising an additional 9 percent in November. The 360Dx Top 30 outpaced the broader markets as ...
NEW YORK – Roche said Tuesday that its point-of-care test for the diagnosis of whooping cough and other Bordetella infections has received 510(k) clearance and CLIA waiver from the US Food and Drug ...
NEW YORK – What were the articles that gained the most interest from 360Dx readers last week? Here are the top five: ...
NEW YORK – Truvian announced Tuesday that it has received 510(k) clearance from the US Food and Drug Administration for its multimodal benchtop analyzer. The TruVerus instrument integrates clinical ...
NEW YORK – Diagnostics firm IdentifySensors Biologics has recently demonstrated proof of concept for the use of its electrochemical sensor-based diagnostic platform Check4 for cancer testing and is ...
The funding will support a collaboration between ProtonDx and Imperial College London to evaluate a host gene expression test on a next-gen test system.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback